Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

Klaus Podar, Xavier Leleu

Research output: Journal article (peer-reviewed)Review article

27 Citations (Scopus)


Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen. The present introductory article of the Special Issue on "Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond" summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.

Original languageEnglish
Article number5154
Issue number20
Publication statusPublished - 01 Oct 2021


Dive into the research topics of 'Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond'. Together they form a unique fingerprint.

Cite this